liraglutide / Generic mfg. - LARVOL DELTA

Atypical Antipsychotics-Induced Glucose and Lipid Metabolism Disorders and Therapeutic Intervention. (PubMed, J Appl Toxicol) - "Here, we searched the database for original and review articles in English and elucidated the existing mechanisms involved in the pathogenesis of atypical antipsychotic-induced glucose and lipid metabolism disorders, which occur in the hypothalamus, liver, pancreas β-cells, adipose tissue, and skeletal muscle. Furthermore, we summarized chemical therapeutics such as liraglutide and topiramate, which could be used in combination with atypical antipsychotics against metabolic disorders caused by atypical antipsychotics, providing clues for future research and therapeutic strategy development."

Journal • Review • CNS Disorders • Dyslipidemia • Genetic Disorders • Mental Retardation • Metabolic Disorders • Psychiatry • Schizophrenia

GLP-1 receptor agonist liraglutide facilitates rotator cuff healing by reducing tendon cell inflammation and endoplasmic reticulum stress through the GLP-1R-AMPK/SIRT1 pathway. (PubMed, Int Immunopharmacol) - "LIRA effectively promotes tissue regeneration and restores biomechanical strength in a rat rotator cuff injury model. These findings suggest LIRA's therapeutic potential for rotator cuff repair and highlight GLP-1R activation as a key mechanism."

Journal • Inflammation • Musculoskeletal Pain • Pain • IL1B

Sonar-AI discovers first comprehensively described cases of GLP-1 receptor agonist associated thrombocytopenia: Faster, cheaper, and better than the 20th century approach of RADAR/sonar (ASH 2025) - "A search of FAERS captured 54 other users of semaglutide, liraglutide, and tirzepatide with (immune) thrombocytopenia...TriNetX Global Collaborative Database Review showed that among both patients with diabetes and patients with obesity but without diabetes, semaglutide use was associated with a lower risk of thrombocytopenia compared with older diabetes and weight loss medications... The SONAR-AI approach facilitated the first comprehensive description of four cases of GLP-1 receptor agonist-associated thrombocytopenia. This effort was completed in four weeks and cost $500. The four cases have been the first comprehensively described cases submitted to FAERS."

Clinical • Diabetes • Genetic Disorders • Hematological Disorders • Immune Thrombocytopenic Purpura • Metabolic Disorders • Obesity • Thrombocytopenia • Thrombocytopenic Purpura

Impact of GLP-1 agonists on cardiovascular outcomes in patients with sickle cell anemia: A propensity score matched retrospective cohort study (ASH 2025) - "The Glucagon-like peptide-1 receptor agonists (GLP-1 agonists) semaglutide, liraglutide, and dulaglutide have been shown to reduce the risk of major adverse CV events in large-scale prospective trials of patients with type two diabetes mellitus and high CV risk. Our study confirms that SCD is associated with worse CV outcomes and that the use of GLP1 agonists significantly reduces the risk of these endpoints in patients with SCD. These results are comparable to other studies showing worse CV outcomes in SCD patients and add to the growing field of data demonstrating improved CV outcomes with the use of GLP1 agonists. More prospective studies are needed to assess the impact of GLP1 agonist therapy on rates of adverse CV outcomes in various patient populations, including those with hemoglobinopathies."

Retrospective data • Anemia • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Hematological Disorders • Metabolic Disorders • Myocardial Ischemia • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Sickle Cell Disease

Obesity as a chronic disease: the key role of new therapies (PubMed, Assist Inferm Ric) - "The introduction of GLP-1 receptor agonists-such as liraglutide and semaglutide-has transformed obesity management by producing substantial weight reduction and improving risks of diabetes, cardiovascular disease, and sleep apnea...Concerns also include reductions in lean mass, high treatment costs, and misuse driven by social media. Ensuring appropriate use requires medical supervision, preventive strategies, and public awareness efforts."

Journal • Review • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Combination metformin and liraglutide in PCOS: clinical efficacy in women and preclinical insights from gut microbiome modulation in rats. (PubMed, Front Endocrinol (Lausanne)) - "In a separate animal study, female Sprague-Dawley rats were divided into five groups: (1) PCOS model group (letrozole 1 mg/kg orally); (2) MET group (letrozole + metformin 200 mg/kg orally); (3) LIRA group (letrozole + liraglutide 0.2 mg/kg subcutaneously); (4) COM group (letrozole + metformin + liraglutide at above doses); and (5) healthy controls (no treatment). Metformin combined with liraglutide significantly improved metabolic and endocrine characteristics in PCOS women. The associated amelioration of gut microbiota dysbiosis in PCOS rats suggests a potential mechanistic link, which warrants verification in future clinical studies."

Clinical • Journal • Preclinical • Gastrointestinal Disorder • Obesity • Polycystic Ovary Syndrome

Pharmacotherapy for obesity management. (PubMed, S Afr Med J) - "Pharmacotherapy for obesity management can be used for individuals with a BMI ≥30 kg/m2, or ≥27 kg/m2 with adiposity-related complications, in conjunction with medical nutrition therapy, physical activity and psychological interventions (semaglutide 2.4 mg weekly [Level 1a, Grade A] liraglutide 3.0 mg daily [Level 2a, grade B], naltrexone/bupropion 16 mg/180 mg twice a day [BID] [Level 2a, Grade B], orlistat 120 mg three times a day [TID] [Level 2a, Grade B])...Metformin and psychological treatment (such as cognitive behavioural therapy) should be considered for prevention of weight gain in people with severe mental illness who are treated with antipsychotic medications associated with weight gain (Level 1a, Grade A)...9. We do not suggest the use of prescription or over-the-counter medications other than those approved in SA for obesity management (Level 4, Grade D, Consensus)."

Journal • CNS Disorders • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Type 2 Diabetes Mellitus

GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety, a narrative review. (PubMed, Ann Med Surg (Lond)) - "Semaglutide (~7 days) and tirzepatide (~5 days) have long half-lives, requiring discontinuation at least 35 days and 25-35 days, respectively, before conception, while liraglutide requires ≥3 days...Alternatives such as metformin, lifestyle modification, and bariatric surgery remain safer options...Preconception discontinuation timed to each agent's half-life is prudent to minimize potential fetal exposure. Prospective studies and pregnancy registries are needed to confirm reproductive safety and refine guidance."

Journal • Review • Diabetes • Genetic Disorders • Infertility • Metabolic Disorders • Obesity • Polycystic Ovary Syndrome • Sexual Disorders • Type 2 Diabetes Mellitus

Signatures of proteomics and glycoproteomics revealed liraglutide ameliorates MASLD by regulating specific metabolic homeostasis in mice. (PubMed, J Pharm Anal) - "A Lira hydrogel formulation (Lira@fibrin (Fib) Gel) was developed to extend drug dosing intervals, offering enhanced therapeutic efficacy in managing chronic metabolic diseases. Our study demonstrated the importance of glycosylation regulation in the therapeutic effects of Lira on MASLD, identifying potential molecular targets and advancing its clinical application for MASLD treatment."

Journal • Preclinical • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis. (PubMed, Addict Sci Clin Pract) - "Observational studies suggest a decrease in alcohol-related events, but RCTs have effects on alcohol consumption and craving that remain non-significant. Larger RCTs are needed."

Journal • Retrospective data • Addiction (Opioid and Alcohol)

Glucagon-like peptide-1 receptor (GLP-1R) agonists prevent tributyltin-induced muscle atrophy/wasting via restoring GLP-1R signaling in vitro and in mice. (PubMed, Ecotoxicol Environ Saf) - "GLP-1R agonists (GLP-1RAs), exendin-4 (Ex-4) and liraglutide (Lira), were tested in C2C12 myotubes (25-500 nM) exposed to TBT (0.25 μM) and in mice orally administered TBT (25 μg/kg/day) with Ex-4 (2.5 μg/kg/day) for 8 weeks. GLP-1R expression in soleus muscle, downregulated by TBT, was restored with Ex-4. These findings demonstrate that GLP-1RAs protect against TBT-induced muscle wasting in vitro, with Ex-4 showing in vivo efficacy through restoration of GLP-1R expression and normalization of apoptosis- and atrophy-related signaling."

Journal • Preclinical • Muscular Atrophy • Myositis

The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis. (PubMed, J R Soc Med) - "This analysis highlights agent-specific neuroprotective profiles: SGLT2 inhibitors, especially high-dose dapagliflozin, may mitigate the onset of delirium and depression, while GLP-1 receptor agonists, notably dulaglutide and liraglutide, may enhance cognitive function. These findings warrant consideration in selecting antihyperglycemic therapies for individuals at elevated neuropsychiatric risk."

Journal • Retrospective data • Alzheimer's Disease • CNS Disorders • Dementia • Depression • Diabetes • Mental Retardation • Metabolic Disorders • Mood Disorders • Psychiatry • Type 2 Diabetes Mellitus

GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study. (PubMed, J Pediatr Endocrinol Metab) - "This first longitudinal report of GLP-1RA use in youth with T1D and obesity shows clinically meaningful improvements in weight, glycemia, and insulin requirements, supporting the potential role of GLP-1RA as adjunct therapy. Larger prospective studies are needed to guide clinical practice."

Journal • Retrospective data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Pediatrics • Type 1 Diabetes Mellitus

Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis. (PubMed, EClinicalMedicine) - "GLP-1 RAs studied were Semaglutide, liraglutide, dulaglutide, exenatide, and tripeptide. Large, dedicated RCTs are needed to confirm efficacy and define optimal therapeutic strategies. No funding was received for this study."

Journal • Retrospective data • Addiction (Opioid and Alcohol) • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review. (PubMed, Cureus) - "Its therapeutic potential was long realized, leading to the development of the first GLP-1 receptor agonist, exenatide, followed by liraglutide, dulaglutide, semaglutide, and tirzepatide...Alongside resmetirom, semaglutide is currently approved for the treatment of non-cirrhotic MASH with moderate-to-advanced fibrosis. Safety considerations include gastrointestinal intolerance, hypoglycemia, rare pancreaticobiliary events, and theoretical concerns of thyroid C-cell tumors, though human risk remains minimal. In summary, semaglutide extends the armamentarium of the hepatologist against the most common liver disease worldwide."

Journal • Review • Cardiovascular • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Hypoglycemia • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Oncology • Thyroid Gland Carcinoma • Type 2 Diabetes Mellitus

Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation. (PubMed, Medicine (Baltimore)) - "No significant statistical difference was found between GLP-1 agonists and other obesity and diabetes drugs regarding suicide/suicidal ideation. In a subgroup analysis, suicide was higher in patients on liraglutide compared to semaglutide, with no significant difference between semaglutide and monjaro. Randomized controlled trials that assess the association between GLP-1 agonists and suicidality are highly recommended."

Clinical • Journal • Retrospective data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Psychiatry • Suicidal Ideation

Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis. (PubMed, BMJ Open) - "Semaglutide, tirzepatide and liraglutide are approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of type 2 diabetes mellitus and overweight...Findings of this systematic review will be published in international peer-reviewed scientific journals. CRD42024623312."

Journal • Retrospective data • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Myocardial Infarction • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

Generic Liraglutide - Overlooked but Not Forgotten. (PubMed, N Engl J Med) - No abstract available

Journal

Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis. (PubMed, Cureus) - "Efpeglenatide ranked highest for both MACE (OR: 0.74; 95% CI: 0.62-0.87; SUCRA: 81.5%) and renal outcomes (OR: 0.68; 95% CI: 0.57-0.81; SUCRA: 81.33%), underscoring its clinical significance over other effective agents such as albiglutide and semaglutide. Albiglutide, semaglutide, dulaglutide, and liraglutide also provided significant benefits, albeit with lower rankings. No major inconsistency or publication bias was detected. In conclusion, this NMA reinforces the class-wide cardiorenal benefits of GLP-1 receptor agonists while emphasizing variations in efficacy among individual agents, the limited evidence base for certain drugs, and the need for future head-to-head trials specifically designed to evaluate cardiovascular and renal endpoints."

Journal • Retrospective data • Review • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon. (PubMed, J Obes) - "Currently, liraglutide, semaglutide, and tirzepatide are FDA-approved for obesity treatment, while other agents are used off-label...Novel agents including CagriSema and higher dose oral semaglutide are advancing through clinical trials, while pivotal trial results for orforglipron, mazdutide, retatrutide, and survodutide are anticipated to further expand the therapeutic landscape...The convergence of pharmacological innovation, digital health strategies, and equitable care initiatives is expected to revolutionize obesity therapeutics in the coming decade. Priorities for future research include sustaining long-term weight loss, establishing disease-modifying potential in nonmetabolic disorders, and addressing health equity concerns to ensure broader global benefit."

Journal • Review • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Diabetes • Dyslipidemia • Genetic Disorders • Heart Failure • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations. (PubMed, Diabetes Obes Metab) - "GLP-1RAs are generally not cost-effective for obesity treatment in patients without diabetes in HICs from a healthcare/payer perspective. However, they may be cost-effective in subgroups evaluated over longer time horizons. Most included studies focused on weight-related outcomes, potentially underestimating the broader economic value of GLP-1RAs. This pooled economic evidence may inform the decision-making process."

HEOR • Journal • Retrospective data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Comment on "Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis". (PubMed, Diabetes Obes Metab) - No abstract available

Journal • IGF1

GLP-1 receptor agonists in Alzheimer's and Parkinson's disease: endocrine pathways, clinical evidence, and future directions. (PubMed, Front Endocrinol (Lausanne)) - "Early clinical trials in AD have produced mixed cognitive signals, though they have shown intriguing biological effects, such as preserved cerebral glucose metabolism with liraglutide on FDG-PET scans. In contrast, the evidence in PD has been more consistent, with agents like exenatide and lixisenatide demonstrating motor benefits, although one trial with a pegylated exendin (NLY01) did not meet its primary endpoint. The definitive test will come from large, ongoing phase 3 programs, such as the EVOKE and EVOKE+ trials for semaglutide. Should these trials are successful, GLP-1RAs could become a cornerstone of earlier, mechanism-based intervention strategies for neurodegenerative diseases."

Journal • Review • Alzheimer's Disease • CNS Disorders • Diabetes • Genetic Disorders • Inflammation • Metabolic Disorders • Movement Disorders • Obesity • Parkinson's Disease • Type 2 Diabetes Mellitus

Assessing the Oncological Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis. (PubMed, Cureus) - "However, varying incidences of neoplasms were observed, with liraglutide showing a statistically significant odds ratio of 2.8150 for cancer risk...Although GLP-1 receptor agonists effectively manage weight and glycemic control in overweight/obese patients, their association with increased cancer risk warrants cautious application, especially in individuals with a predisposition to thyroid or pancreatic cancers. Further studies are needed to conclusively determine the safety profile of these therapies."

Clinical • Journal • Retrospective data • Review • Genetic Disorders • Metabolic Disorders • Obesity • Oncology • Pancreatic Cancer • Solid Tumor • Thyroid Gland Carcinoma • Type 2 Diabetes Mellitus

GLP-1 receptor agonists on WHO-EML 2025 list: major breakthrough bounded by persistent challenge. (PubMed, J Diabetes Metab Disord) - "Notably, the inclusion of glucagon-like peptide-1 (GLP-1) receptor agonists-semaglutide, liraglutide, dulaglutide-and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide, represents a paradigm shift in the management of type 2 diabetes mellitus (T2DM) and obesity...However, challenges persist, including financial constraints, limited healthcare infrastructure, and risks of irrational use, particularly for obesity alone. Effective implementation through national policies, training, and rational prescribing frameworks is essential to translating this global milestone into tangible public health benefits and to reducing the growing burden of diabetes and obesity worldwide."

Journal • Cardiovascular • Chronic Kidney Disease • Cystic Fibrosis • Dermatology • Diabetes • Genetic Disorders • Hematological Disorders • Hemophilia • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Obesity • Oncology • Psoriasis • Pulmonary Disease • Rare Diseases • Renal Disease • Respiratory Diseases • Type 2 Diabetes Mellitus